

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

A randomized, open label, single dose, crossover, bioequivalence study of Fexofenadine 120mg tablet of Jaber Ebne Hayyan Pharm. Co., IRAN in comparison of Telfast 120mg tablet of Sanofi in 24 healthy adult subjects under fasting condition

Protocol summary

Study aim

A randomized, crossover bioequivalence study of single dose of test formulation (Fexofenadine 120mg tablet of Jaber Ebne Hayyan Pharm. Co.) in comparison of reference product (Telfast 120mg tablet) by means of AUC_{0-t} (Area Under the Curve up to the last measurable concentration) and C_{max} (maximum plasma concentration) in healthy adult human subjects under fasting conditions.

Design

A randomized, open label, single dose, crossover, bioequivalence study in 24 healthy subjects under fasting condition

Settings and conduct

This study is carried out in Core Research Center of Zahedan University of Medical Sciences located in Imam Ali Hospital in Zahedan. There is a separate space for sampling and forecasting emergency situations in order to accommodate and rest the volunteers. This crossover and open label study was performed on 24 healthy volunteers. The volunteers' health is verified by the project physician prior to entry into the study, and the volunteers' status is regularly monitored by the project physician on the day of drug administration. This study will be covered by insurance in order to compensate for any adverse effects.

Participants/Inclusion and exclusion criteria

Main Inclusion criteria: Healthy subjects aged between 18 -50 years old and weighted between 50 - 100 kg\\
Main exclusion criteria: Clinically relevant deviations from normal; Donation a unit of blood or participated in another clinical trial within the last two months; History of drug or alcohol abuse; Used any medication within 7-14 days before the first treatment;

Intervention groups

Intervention: Single dose of two Fexofenadine 120mg

tablets of Jaber Ebne Hayyan Pharm. Co, IRAN Control:
Single dose of two Telfast 120mg tablets of Sanofi

Main outcome variables

Plasma concentration of Hydrochlorothiazide at 0 (before dosing), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 24.0 & 48.0 hr. after dosing

General information

Reason for update

Changing the drug dose from 180 mg tablet to 120 mg tablet

Acronym

IRCT registration information

IRCT registration number: **IRCT20190706044111N25**
Registration date: **2022-01-01, 1400/10/11**
Registration timing: **prospective**

Last update: **2023-08-20, 1402/05/29**

Update count: **1**

Registration date

2022-01-01, 1400/10/11

Registrant information

Name

Ladan Tayebi

Name of organization / entity

Pars Biopharmacy Research Co.

Country

Iran (Islamic Republic of)

Phone

+98 21 8895 6061

Email address

l.tayebi@parsbiopharmacy.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-01-21, 1400/11/01

Expected recruitment end date

2022-09-22, 1401/06/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

A randomized, open label, single dose, crossover, bioequivalence study of Fexofenadine 120mg tablet of Jaber Ebne Hayyan Pharm. Co., IRAN in comparison of Telfast 120mg tablet of Sanofi in 24 healthy adult subjects under fasting condition

Public title

Bioequivalence study of Fexofenadine 120mg tablet of Jaber Ebne Hayyan Pharm. Co., IRAN

Purpose

Other

Inclusion/Exclusion criteria**Inclusion criteria:**

- Aged between 18 - 50 years - Body weight between 50 - 100 kg - Having good health on the basis of medical history and physical & clinical examination - Understand the procedures and give written informed consent

Exclusion criteria:

Subject had undergone surgery of the gastro-intestinal tract treatment. Subject had donated a unit of blood or participated in another clinical trial, within the last two months before the first Subject had a history of drug or alcohol abuse. Subject who smokes more than 10 cigarettes per day. Subject had used any prescription medication within 14 days, or any non-prescription medication within 7 days, before the first treatment.

AgeFrom **18 years** old to **50 years** old**Gender**

Both

Phase

Bioequivalence

Groups that have been masked*No information***Sample size**Target sample size: **48**

More than 1 sample in each individual

Number of samples in each individual: **2**

Each volunteer, 2 times take medicine in the study. One-time test product and the other time reference product with at least one week wash-out period

Randomization (investigator's opinion)

Randomized

Randomization description

Using the rand command in Excel software, one of the sequences AB (test-reference product) or BA (reference-test product) is randomly assigned to each volunteer at random.

Blinding (investigator's opinion)

Not blinded

Blinding description**Placebo**

Not used

Assignment

Crossover

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Zahedan University of medical Sciences

Street address

Dr. Hessabi square Zahedan University of Medical Sciences

City

Zahedan

Province

Sistan-va-Balouchestan

Postal code

9816743463

Approval date

2021-12-12, 1400/09/21

Ethics committee reference number

IR.ZAUMS.REC.1400.313

Health conditions studied**1****Description of health condition studied**

allergic rhinitis

ICD-10 code

Z88.9

ICD-10 code description

Allergy status to unspecified drug/meds/biol subst

Primary outcomes**1****Description**

Plasma concentration of fexofenadine

Timepoint

at 0 (before dosing), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 24.0 & 48.0 hr. after dosing

Method of measurement

High Performance Liquid Chromatography (HPLC)

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: two 120mg Fexofenadine tablets, produced by Jaber Ebne Hayyan Pharm. Co. (IRAN), single dose.

Category

Other

2

Description

Control group: Telfast, two 120mg tablets, produced by Sanofi company, single dose.

Category

Other

Recruitment centers

1

Recruitment center

Name of recruitment center

Core Research Lab. of ZAUMS

Full name of responsible person

Ghasemi Marzyeh

Street address

Emam Ali Hospital, Salamat Blv., Khalij-e-Fars Highway

City

Zahedan

Province

Sistan-va-Balouchestan

Postal code

9816743111

Phone

+98 54 3329 5664

Fax

+98 54 3329 5665

Email

crl@zaums.ac.ir

Web page address

<http://crl.zaums.ac.ir/>

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Jaber Ebne Hayyan Pharm. Co..

Full name of responsible person

Saffary Mostafa

Street address

Km 4 Karaj road

City

Tehran

Province

Tehran

Postal code

1398834511

Phone

+98 21 4450 3323

Fax

+98 21 4450 3530

Email

HeadOffice@jaber-pharma.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Jaber Ebne Hayyan Pharm. Co..

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Industry

Person responsible for general inquiries

Contact

Name of organization / entity

Pars Biopharmacy Research Co.

Full name of responsible person

Ladan Tayebi

Position

Managing Director

Latest degree

Medical doctor

Other areas of specialty/work

Medical Pharmacy

Street address

1st floor, Saeidi Dd end, Felestin Ave.

City

Tehran

Province

Tehran

Postal code

1416673971

Phone

+98 21 8895 6061

Fax

+98 21 8896 9958

Email

l.tayebi@parsbiopharmacy.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Pars Biopharmacy Research Co.

Full name of responsible person

Ladan Tayebi

Position

Managing Director

Latest degree

Medical doctor

Other areas of specialty/work

Medical Pharmacy

Street address

1st floor, Saeidi Dd end, Felestin Ave.

City

Tehran

Province

Tehran

Postal code

1416673971

Phone

+98 21 8895 6061

Fax

+98 21 8896 9958

Email

l.tayebi@parsbiopharmacy.com

Person responsible for updating data**Contact****Name of organization / entity**

Pars Biopharmacy Research Co.

Full name of responsible person

Ladan Tayebi

Position

Managing Director

Latest degree

Medical doctor

Other areas of specialty/work

Medical Pharmacy

Street address

1st floor, Saeidi Dd end, Felestin Ave.

City

Tehran

Province

Tehran

Postal code

1416673971

Phone

+98 21 8895 6061

Fax

+98 21 8896 9958

Email

l.tayebi@parsbiopharmacy.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available